Compare PDD Holdings Inc. American Depositary Shares (PDD) vs Tango Therapeutics Inc. (TNGX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
PDD Holdings Inc. American Depositary Shares vs Tango Therapeutics Inc. — how do they compare? PDD Holdings Inc. American Depositary Shares trades at $80.3 (market cap $115.94B), while Tango Therapeutics Inc. trades at $22.2 (market cap $3.74B). The key difference: PDD Holdings Inc. American Depositary Shares is far larger — about 31× Tango Therapeutics Inc.'s market cap, and Tango Therapeutics Inc. is trading nearer its 52-week high, PDD Holdings Inc. American Depositary Shares nearer its low. Which is the better fit depends on your goals.
| PDD | TNGX | |
|---|---|---|
Market Cap | $115.94B | $3.74B |
Volume | 6,241,534 | 3,438,781 |
Sector | Consumer Cyclical | Health |
52-Week High | $138.13 | $32.90 |
52-Week Low | $73.30 | $7.50 |
Enterprise Value | $48.46B | $2.76B |
Typical Hold Time | — | 0 Days |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
PDD Holdings trades at $81.96, up 1.29% with a bullish technical signal despite recent earnings volatility. The stock shows strong fundamentals with a P/E of 8.81 and robust profitability margins (net income margin 20.43%). Recent news highlights investor attention and the company's major investment cycle while facing regulatory and competitive pressures.
The outlook remains cautiously optimistic with a $99.13 consensus price target, though risks include trade policy impacts and execution challenges from PDD's shift to an asset-heavy model. Earnings misses in recent quarters and moderating revenue growth warrant close monitoring for sustained investor confidence.
TNGX trades at $22.22, down 8.07% in the last session, reflecting negative investor reaction to recent earnings misses. The stock shows neutral technical signals with key support at $21 and resistance at $23. Fundamentally, the company maintains a high gross margin of 98.25% but faces significant losses with a net income margin of -229.92% and negative cash flow from operations. Recent news highlights institutional buying interest and upcoming clinical trial developments.
Despite strong analyst support with a $45.91 consensus price target (107% upside), TNGX faces substantial execution risks as a clinical-stage biotech. The company's heavy cash burn and lack of profitability require careful monitoring of pipeline progress. Investment appeal hinges on successful drug development outcomes rather than current financial metrics.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About PDD Holdings Inc. American Depositary Shares
PDD Holdings is a multinational commerce group that owns and operates a portfolio of businesses. Its sourcing, logistics, and fulfillment network supports those businesses and their commerce operations.
Read more on PDD →About Tango Therapeutics Inc.
Tango Therapeutics, Inc. is a clinical-stage biotechnology company focused on precision oncology, developing cancer therapies based on the genetic principle of synthetic lethality, including its PRMT5 inhibitor program.
Read more on TNGX →
